[HTML] nih.gov

[HTML][HTML] Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

S Terrisse, AG Goubet, K Ueda… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually
in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant …
被引用次数：30 相关文章

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

S Terrisse, AG Goubet, K Ueda, AM Thomas… - JOURNAL FOR …, 2022 - iris.unitn.it
Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually in a transient
fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant PC (CRPC) …

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

S Terrisse, AG Goubet, K Ueda… - Journal for …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually
in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant …
[HTML] bmj.com

[HTML][HTML] Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

S Terrisse, AG Goubet, K Ueda, AM Thomas… - … for ImmunoTherapy of …, 2022 - jitc.bmj.com
Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually
in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant …

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

S Terrisse, AG Goubet, K Ueda… - Journal for …, 2022 - search.proquest.com
Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually
in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant …

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer.

S Terrisse, AG Goubet, K Ueda… - … for Immunotherapy of …, 2022 - europepmc.org
Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually
in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant …
[PDF] academia.edu

[PDF][PDF] Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

S Terrisse, AG Goubet, K Ueda, AM Thomas, V Quiniou… - academia.edu
Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually
in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant …
[PDF] unitn.it

[PDF][PDF] Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

S Terrisse, AG Goubet, K Ueda, AM Thomas, V Quiniou… - iris.unitn.it
Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually
in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant …

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer.

S Terrisse, AG Goubet, K Ueda… - … for Immunotherapy of …, 2022 - europepmc.org
Background Prostate cancer (PC) responds to androgen deprivation therapy (ADT) usually
in a transient fashion, progressing from hormone-sensitive PC (HSPC) to castration-resistant …